FI934625A7 - Bentseenifuusioituneiden hydroksisubstituoitujen sykloalkyyli- ja heterosyklisten rengasyhdisteiden sulfoniamidijohdannaisia - Google Patents

Bentseenifuusioituneiden hydroksisubstituoitujen sykloalkyyli- ja heterosyklisten rengasyhdisteiden sulfoniamidijohdannaisia Download PDF

Info

Publication number
FI934625A7
FI934625A7 FI934625A FI934625A FI934625A7 FI 934625 A7 FI934625 A7 FI 934625A7 FI 934625 A FI934625 A FI 934625A FI 934625 A FI934625 A FI 934625A FI 934625 A7 FI934625 A7 FI 934625A7
Authority
FI
Finland
Prior art keywords
fused
benzene
hydroxy
heterocyclic ring
substituted cycloalkyl
Prior art date
Application number
FI934625A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI934625L (fi
FI934625A0 (fi
Inventor
Anthony Marfat
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI934625A0 publication Critical patent/FI934625A0/fi
Publication of FI934625L publication Critical patent/FI934625L/fi
Publication of FI934625A7 publication Critical patent/FI934625A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI934625A 1992-10-21 1993-10-20 Bentseenifuusioituneiden hydroksisubstituoitujen sykloalkyyli- ja heterosyklisten rengasyhdisteiden sulfoniamidijohdannaisia FI934625A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96433792A 1992-10-21 1992-10-21

Publications (3)

Publication Number Publication Date
FI934625A0 FI934625A0 (fi) 1993-10-20
FI934625L FI934625L (fi) 1994-04-22
FI934625A7 true FI934625A7 (fi) 1994-04-22

Family

ID=25508435

Family Applications (1)

Application Number Title Priority Date Filing Date
FI934625A FI934625A7 (fi) 1992-10-21 1993-10-20 Bentseenifuusioituneiden hydroksisubstituoitujen sykloalkyyli- ja heterosyklisten rengasyhdisteiden sulfoniamidijohdannaisia

Country Status (23)

Country Link
US (1) US5641789A (enExample)
EP (1) EP0665842A1 (enExample)
JP (1) JPH07508534A (enExample)
KR (1) KR950704309A (enExample)
CN (1) CN1090282A (enExample)
AP (1) AP9300578A0 (enExample)
AU (1) AU5536794A (enExample)
BR (1) BR9307277A (enExample)
CA (1) CA2146261A1 (enExample)
CZ (1) CZ100095A3 (enExample)
FI (1) FI934625A7 (enExample)
HR (1) HRP931297A2 (enExample)
HU (1) HUT68323A (enExample)
IL (1) IL107294A0 (enExample)
MA (1) MA23009A1 (enExample)
MX (1) MX9306528A (enExample)
NO (1) NO303224B1 (enExample)
PL (1) PL308474A1 (enExample)
RU (1) RU95109929A (enExample)
SI (1) SI9300554A (enExample)
TW (1) TW265335B (enExample)
WO (1) WO1994008996A1 (enExample)
ZA (1) ZA937782B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539128A (en) * 1994-11-30 1996-07-23 Pfizer Inc. Processes and intermediates for preparing cis(+)3-[4,6-dihydroxy chroman-3-ylmethyl]-4-methoxyaniline
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
SK31399A3 (en) * 1996-09-16 2000-05-16 Pfizer Processes and intermediates for preparing substituted chromanol derivatives
ZA981080B (en) * 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
GB9800039D0 (en) * 1998-01-02 1998-03-04 Univ Cardiff Benzyl and benzylidene tetralins and derivatives
RU2182004C1 (ru) * 2001-02-22 2002-05-10 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Лекарственный препарат для парентерального применения
JP4358515B2 (ja) * 2001-04-10 2009-11-04 タカラバイオ株式会社 治療剤
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US7507531B2 (en) * 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) * 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
EP1579010A4 (en) * 2002-10-17 2010-07-21 Decode Genetics Ehf SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION AND METHODS OF TREATMENT
CA2539276A1 (en) * 2003-09-17 2005-03-31 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20060210514A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Skin protection and moisturizing compositions and method of making the same
CN119912349B (zh) * 2023-10-31 2025-11-21 中国石油天然气股份有限公司 一种可降解凝胶用交联剂、制备方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059609A (en) * 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
WO1990015801A1 (en) * 1989-06-22 1990-12-27 Pfizer Inc. Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases

Also Published As

Publication number Publication date
MX9306528A (es) 1994-06-30
MA23009A1 (fr) 1994-07-01
CN1090282A (zh) 1994-08-03
TW265335B (enExample) 1995-12-11
AU5536794A (en) 1994-05-09
HUT68323A (en) 1995-06-28
AP9300578A0 (en) 1995-04-07
FI934625L (fi) 1994-04-22
EP0665842A1 (en) 1995-08-09
IL107294A0 (en) 1994-01-25
KR950704309A (ko) 1995-11-17
BR9307277A (pt) 1999-05-11
HRP931297A2 (en) 1996-08-31
NO951506L (no) 1995-04-20
CA2146261A1 (en) 1994-04-28
FI934625A0 (fi) 1993-10-20
CZ100095A3 (en) 1995-11-15
SI9300554A (en) 1995-04-30
NO951506D0 (no) 1995-04-20
JPH07508534A (ja) 1995-09-21
ZA937782B (en) 1995-04-20
US5641789A (en) 1997-06-24
PL308474A1 (en) 1995-08-07
HU9302969D0 (en) 1993-12-28
NO303224B1 (no) 1998-06-15
WO1994008996A1 (en) 1994-04-28
RU95109929A (ru) 1997-03-20

Similar Documents

Publication Publication Date Title
NO951506D0 (no) Sulfonamidderivater av benzenkondenserte hydroksysubstituerte cykloalkyl- og heterocykliske ringforbindelser
NO932127D0 (no) Imidatderivater av farmasoeytisk nyttige antikonvulserendesulfamater
DE69132006D1 (de) Thiazolederivate als inhibitoren von aktivem sauerstoff
FI944550L (fi) Öljyontelo-proteiinien cis-elementit säätelysignaaleina
FI942911L (fi) 2-imidatsoliini-5-oni- ja 2-imidatsoliini-5-tionifungisidien optisesti aktiiviset johdannaiset
FI933213A7 (fi) Uudet bentsimidatsolin piperidiinijohdannaiset
AU3261293A (en) Heterocyclic sulfonamide derivatives as antagonists of paf and angiotensin II
DK137590A (da) N-imidazolyl- og n-imidazolylmethylderivater af substituerede bicycliske forbindelser
NO932860D0 (no) Fremgangsmaate for fremstilling av kalsium-l-askorbat-2-fosfat
FI944016A0 (fi) Makrolidien fluorisokerijohdannaiset
FI943386L (fi) CNS-aktiivisuuden omaavia tratsodonin alkyylijohdannaisia
FI973500A0 (fi) 3-pyrrolidylideeni-2-oni-kefalosporiinien johdannaiset
NO944906D0 (no) Ny anvendelse av benzo[gÅkinolinderivater
NO940190D0 (no) Anvendelse av x-ketoglutarat
DK104489D0 (da) Anvendelse af triazolderivater
NO934602D0 (no) Fremgangsmaate for fremstilling av polypeptider
FI945579L (fi) Huokoisten materiaalien modifiointi
LV10277A (lv) Cefalosporina atvasinajumi
NO920272D0 (no) Hydrofile-hydrofobe derivater av polygalaktomannaner inneholdende tertiaer aminfunksjonalitet
FI944015L (fi) Makrolidien 2-aminosokerijohdannaiset
BR9306699A (pt) Derivados do triazoliletanol
KR930026760U (ko) Tvcr의 개선된 구성
NO920033D0 (no) Fremgangsmaate for fremstilling av heterocykliske forbindelser
MX9203741A (es) Derivados de interleuqina-1&
NO902476L (no) N-imidazolyl- og n-imidazolylmetyl-derivater av substituerte bicykliske forbindelser.

Legal Events

Date Code Title Description
FD Application lapsed
FD Application lapsed